A phase II open label randomized multicenter trial of TSU-68 in combination with docetaxel versus docetaxel alone in patients with metastatic breast cancer previously treated with an anthracycline.

Trial Profile

A phase II open label randomized multicenter trial of TSU-68 in combination with docetaxel versus docetaxel alone in patients with metastatic breast cancer previously treated with an anthracycline.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Orantinib (Primary) ; Docetaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 09 Apr 2014 Results published in Investigational New Drugs.
    • 03 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top